CGA and neoplasm: The first therapies were attempted with [111In-DTPA0]-octreotide and resulted in reduced tumour markers such as chromogranin A (CgA, the general NE marker) and 5-hydroxy indole acetic acid (5-HIAA, the serotonin metabolite), but only occasionally objective tumour responses (Fjälling et al, 1996; McCarthy et al, 1998; Krenning et al, 1999).